Advertisement
Screener

NeoGenomics, Inc. (NEO) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

2.9 / 5 stars · 42/72 Roast Me

NeoGenomics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 57.66K shares, a 2968.65% increase year-over-year.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 84.12K shares, a 1067.71% increase year-over-year.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 26.04K shares, a 33.09% decline year-over-year.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 35.12K shares, a 91.48% decline from fiscal 2024.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 412.44K shares, a 47.75% increase from fiscal 2023.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 279.15K shares, a 70.59% decline from fiscal 2022.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 949.26K shares, a 30.84% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2026-06-3057.66K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28
167.82K shares
derived: sum of 4 quarters · filed 2026-07-28
2026-03-3184.12K shares
10-Q · filed 2026-04-28
112.04K shares
derived: sum of 4 quarters · filed 2026-04-28
2025-12-3126.04K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
35.12K shares
10-K · filed 2026-02-17
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
48.00K shares
derived: sum of 4 quarters · filed 2026-02-17
2025-06-301.88K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29
127.15K shares
derived: sum of 4 quarters · filed 2026-02-17
2025-03-317.20K shares
10-Q · filed 2025-04-29
406.88K shares
derived: sum of 4 quarters · filed 2026-02-17
2024-12-3138.92K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
412.44K shares
10-K · filed 2026-02-17
2024-09-3079.15K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
429.63K shares
derived: sum of 4 quarters · filed 2026-02-17
2024-06-30281.61K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30
438.42K shares
derived: sum of 4 quarters · filed 2026-02-17
2024-03-3112.76K shares
10-Q · filed 2024-04-30
216.88K shares
derived: sum of 4 quarters · filed 2026-02-17
2023-12-3156.10K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
279.15K shares
10-K · filed 2026-02-17
2023-09-3087.94K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
367.75K shares
derived: sum of 4 quarters · filed 2025-02-18
2023-06-3060.07K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
517.78K shares
derived: sum of 4 quarters · filed 2025-02-18
2023-03-3175.03K shares
10-Q · filed 2023-05-09
552.68K shares
derived: sum of 4 quarters · filed 2025-02-18
2022-12-31144.70K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
949.26K shares
10-K · filed 2025-02-18
2022-09-30237.97K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
1.25M shares
derived: sum of 4 quarters · filed 2024-02-20
2022-06-3094.97K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
1.33M shares
derived: sum of 4 quarters · filed 2024-02-20
2022-03-31471.61K shares
10-Q · filed 2022-05-09
1.58M shares
derived: sum of 4 quarters · filed 2024-02-20
2021-12-31440.61K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20
1.37M shares
10-K · filed 2024-02-20
2021-09-30319.65K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
1.97M shares
derived: sum of 4 quarters · filed 2023-02-24
2021-06-30352.14K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
2.23M shares
derived: sum of 4 quarters · filed 2023-02-24
2021-03-31260.17K shares
10-Q · filed 2021-05-06
2.07M shares
derived: sum of 4 quarters · filed 2023-02-24
2020-12-311.03M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
2.31M shares
10-K · filed 2023-02-24
2020-09-30584.85K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
2.15M shares
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30187.17K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
1.85M shares
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31504.13K shares
10-Q · filed 2020-04-29
2.18M shares
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31869.58K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
2.31M shares
10-K · filed 2022-02-25
2019-09-30289.08K shares
10-Q · filed 2020-10-29
1.92M shares
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30515.53K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
1.69M shares
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31635.26K shares
10-Q · filed 2019-05-08
2.13M shares
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31475.89K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
1.57M shares
10-K · filed 2021-02-25
2018-09-3063.75K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
1.16M shares
derived: sum of 4 quarters · filed 2020-02-28
2018-06-30958.08K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
1.27M shares
derived: sum of 4 quarters · filed 2020-02-28
2018-03-3172.50K shares
10-Q · filed 2018-05-08
427.42K shares
derived: sum of 4 quarters · filed 2020-02-28
2017-12-3162.25K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28
565.57K shares
10-K · filed 2020-02-28
2017-09-30173.50K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
591.82K shares
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30119.17K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
809.74K shares
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31210.65K shares
10-Q · filed 2017-05-09
1.48M shares
derived: sum of 4 quarters · filed 2019-02-26
2016-12-3188.50K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
2.48M shares
10-K · filed 2019-02-26
2016-09-30391.42K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
2.60M shares
derived: sum of 4 quarters · filed 2018-03-13
2016-06-30785.30K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
2.29M shares
derived: sum of 4 quarters · filed 2018-03-13
2016-03-311.22M shares
10-Q · filed 2016-05-10
1.64M shares
derived: sum of 4 quarters · filed 2018-03-13
2015-12-31202.97K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
492.09K shares
10-K · filed 2018-03-13
2015-09-3081.50K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06
2015-06-30139.75K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31
2015-03-3167.88K shares
10-Q · filed 2015-05-11
2014-12-312.39M shares
10-K · filed 2017-03-14
2013-12-31439.00K shares
10-K · filed 2016-04-18
2012-12-31197.21K shares
10-K · filed 2015-03-03
2011-12-31382.50K shares
10-K · filed 2014-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B